125 related articles for article (PubMed ID: 25687841)
1. Double somatic mosaic mutations in TET2 and DNMT3A--origin of peripheral T cell lymphoma in a case.
Nguyen TB; Sakata-Yanagimoto M; Nakamoto-Matsubara R; Enami T; Ito Y; Kobayashi T; Obara N; Hasegawa Y; Chiba S
Ann Hematol; 2015 Jul; 94(7):1221-3. PubMed ID: 25687841
[No Abstract] [Full Text] [Related]
2. TET2 and DNMT3A mutations in human T-cell lymphoma.
Couronné L; Bastard C; Bernard OA
N Engl J Med; 2012 Jan; 366(1):95-6. PubMed ID: 22216861
[No Abstract] [Full Text] [Related]
3. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
Sakata-Yanagimoto M; Enami T; Yoshida K; Shiraishi Y; Ishii R; Miyake Y; Muto H; Tsuyama N; Sato-Otsubo A; Okuno Y; Sakata S; Kamada Y; Nakamoto-Matsubara R; Tran NB; Izutsu K; Sato Y; Ohta Y; Furuta J; Shimizu S; Komeno T; Sato Y; Ito T; Noguchi M; Noguchi E; Sanada M; Chiba K; Tanaka H; Suzukawa K; Nanmoku T; Hasegawa Y; Nureki O; Miyano S; Nakamura N; Takeuchi K; Ogawa S; Chiba S
Nat Genet; 2014 Feb; 46(2):171-5. PubMed ID: 24413737
[TBL] [Abstract][Full Text] [Related]
4. Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2.
van den Akker EB; Pitts SJ; Deelen J; Moed MH; Potluri S; van Rooij J; Suchiman HE; Lakenberg N; de Dijcker WJ; Uitterlinden AG; Kraaij R; Hofman A; de Craen AJ; Houwing-Duistermaat JJ; van Ommen GJ; ; Cox DR; van Meurs JB; Beekman M; Reinders MJ; Slagboom PE
Blood; 2016 Mar; 127(11):1512-5. PubMed ID: 26825711
[No Abstract] [Full Text] [Related]
5. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.
Dobay MP; Lemonnier F; Missiaglia E; Bastard C; Vallois D; Jais JP; Scourzic L; Dupuy A; Fataccioli V; Pujals A; Parrens M; Le Bras F; Rousset T; Picquenot JM; Martin N; Haioun C; Delarue R; Bernard OA; Delorenzi M; de Leval L; Gaulard P
Haematologica; 2017 Apr; 102(4):e148-e151. PubMed ID: 28082343
[No Abstract] [Full Text] [Related]
6. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
7. Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.
Raess PW; Cascio MJ; Fan G; Press R; Druker BJ; Brewer D; Spurgeon SE
Am J Hematol; 2017 Jan; 92(1):E6-E8. PubMed ID: 27761930
[No Abstract] [Full Text] [Related]
8. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
9. Lineage restriction analyses in CHIP indicate myeloid bias for
Buscarlet M; Provost S; Zada YF; Bourgoin V; Mollica L; Dubé MP; Busque L
Blood; 2018 Jul; 132(3):277-280. PubMed ID: 29764839
[TBL] [Abstract][Full Text] [Related]
10. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
11. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Palomero T; Couronné L; Khiabanian H; Kim MY; Ambesi-Impiombato A; Perez-Garcia A; Carpenter Z; Abate F; Allegretta M; Haydu JE; Jiang X; Lossos IS; Nicolas C; Balbin M; Bastard C; Bhagat G; Piris MA; Campo E; Bernard OA; Rabadan R; Ferrando AA
Nat Genet; 2014 Feb; 46(2):166-70. PubMed ID: 24413734
[TBL] [Abstract][Full Text] [Related]
12. A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
Fernandez-Pol S; Ma L; Joshi RP; Arber DA
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):416-422. PubMed ID: 29629950
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
Jain P; Verstovsek S; Wang W; Loghavi S; Torres HA; Estrov Z; Patel KP; Pemmaraju N
Leuk Lymphoma; 2016 Aug; 57(8):1969-73. PubMed ID: 26700872
[No Abstract] [Full Text] [Related]
14. Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness.
Ostrander EL; Kramer AC; Mallaney C; Celik H; Koh WK; Fairchild J; Haussler E; Zhang CRC; Challen GA
Stem Cell Reports; 2020 Apr; 14(4):551-560. PubMed ID: 32220332
[TBL] [Abstract][Full Text] [Related]
15. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
Lemonnier F; Couronné L; Parrens M; Jaïs JP; Travert M; Lamant L; Tournillac O; Rousset T; Fabiani B; Cairns RA; Mak T; Bastard C; Bernard OA; de Leval L; Gaulard P
Blood; 2012 Aug; 120(7):1466-9. PubMed ID: 22760778
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
17. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
Kurt H; Khoury JD; Medeiros LJ; Huh YO
Br J Haematol; 2018 May; 181(3):305. PubMed ID: 29411884
[No Abstract] [Full Text] [Related]
20. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
